Lyell Immunopharma annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Depreciation & Amortization Growth & History (LYEL)
Lyell Immunopharma's depreciation and amortization was $11.5M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.5M | −$8.1M | −41.22% |
| 2024 | 2024-12-31 | $19.6M | −$619,000 | −3.06% |
| 2023 | 2023-12-31 | $20.3M | $2.2M | +12.38% |
| 2022 | 2022-12-31 | $18.0M | $4.4M | +32.27% |
| 2021 | 2021-12-31 | $13.6M | $9.3M | +217.28% |
| 2020 | 2020-12-31 | $4.3M | $3.0M | +241.88% |
| 2019 | 2019-12-31 | $1.3M | — | — |
Lyell Immunopharma quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.2M | −$913,000 | −29.12% |
| Q1 2026 | 2026-03-31 | $2.3M | −$1.1M | −32.23% |
| Q4 2025 | 2025-12-31 | $2.4M | — | — |
| Q3 2025 | 2025-09-30 | $2.6M | −$2.1M | −45.17% |
| Q2 2025 | 2025-06-30 | $3.1M | −$1.8M | −36.03% |
| Q1 2025 | 2025-03-31 | $3.4M | −$1.6M | −31.51% |
| Q3 2024 | 2024-09-30 | $4.7M | −$424,000 | −8.31% |
| Q2 2024 | 2024-06-30 | $4.9M | −$161,000 | −3.18% |
| Q1 2024 | 2024-03-31 | $5.0M | −$3,000 | −0.06% |
| Q3 2023 | 2023-09-30 | $5.1M | $483,000 | +10.45% |
| Q2 2023 | 2023-06-30 | $5.1M | $891,000 | +21.36% |
| Q1 2023 | 2023-03-31 | $5.0M | $840,000 | +20.06% |
| Q3 2022 | 2022-09-30 | $4.6M | $530,000 | +12.96% |
| Q2 2022 | 2022-06-30 | $4.2M | $1.2M | +38.57% |
| Q1 2022 | 2022-03-31 | $4.2M | $2.2M | +113.84% |
| Q3 2021 | 2021-09-30 | $4.1M | $3.0M | +270.56% |
| Q2 2021 | 2021-06-30 | $3.0M | — | — |
| Q1 2021 | 2021-03-31 | $2.0M | — | — |
| Q3 2020 | 2020-09-30 | $1.1M | — | — |
Lyell Immunopharma depreciation and amortization trends
Over the last five fiscal years, Lyell Immunopharma's depreciation and amortization increased from $4.3M to $11.5M, a change of $7.2M. The latest reported quarter, Q2 2026, shows $2.2M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗